Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening

Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening
Allogene expands global trial

Allogene Therapeutics announced the expansion of its pivotal Phase 2 ALPHA3 trial to include South Korea and Australia, bringing the total number of study sites to more than 80 worldwide.

This global push comes as the company accelerates momentum for cema-cel in first-line large B-cell lymphoma (1L LBCL). Screening for the trial is expected to begin in the second quarter of 2026, reflecting Allogene Therapeutics' commitment to advancing cell therapy innovations on an international scale.

Allogene has previously released interim ALPHA3 data indicating early potential for allogeneic CAR T therapy in LBCL treatment, according to trial results. The company continues to focus on driving innovation in CAR T approaches, targeting broader patient access and new developments in cell-based treatments, as reported earlier. These efforts form the backdrop for the latest international expansion.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.